Literature DB >> 3698178

A rapid chromatographic procedure for the determination of adriamycin, daunomycin and their 13-OH metabolites adriamycinol and daunomycinol.

N Erb, R Erttmann, G Landbeck.   

Abstract

A rapid chromatographic procedure for the quantitative determination of the anthracycline antibiotics adriamycin and daunorubicin and their chief metabolites adriamycinol and daunorubicinol in plasma and urine is described. The extraction is performed using SEP-PAK silica cartridges. After filtration the eluate is chromatographed on a reversed-phase column.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3698178     DOI： 10.1007/bf00299866

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  5 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography.

Authors:  R Hulhoven; J P Desager
Journal:  J Chromatogr       Date:  1976-09-29

Review 3.  Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations.

Authors:  H L Davis; T E Davis
Journal:  Cancer Treat Rep       Date:  1979-05

4.  Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.

Authors:  S Eksborg; H Ehrsson; B Andersson; M Beran
Journal:  J Chromatogr       Date:  1978-06-01

5.  Measurement of adriamycin (doxorubicin) and its metabolites in human plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.

Authors:  R N Pierce; P I Jatlow
Journal:  J Chromatogr       Date:  1979-12-01
  5 in total
  3 in total

1.  Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography.

Authors:  David L Chin; Bert L Lum; Branimir I Sikic
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-11-05       Impact factor: 3.205

2.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence.

Authors:  R Erttmann; N Erb; A Steinhoff; G Landbeck
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.

Authors:  D L de Valeriola; D D Ross; A Forrest; D P Cuddy; M J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.